All In Biotech

Drug Trial Radar · NCT07937748

Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa

A Pilot Open-Label Trial Assessing Safety of Filsuvez in Patients With Dystrophic or Junctional Epidermolysis Bullosa Under Age 6 Months

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jan 1, 2029

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Medical University of South CarolinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chiesi USA, Inc.
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 5 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size, disease activity, pain, and family burden during and after treatment.

Conditions

  • Dystrophic Epidermolysis Bullosa
  • Junctional Epidermolysis Bullosa

Interventions

  • Filsuvez topical gel: 10% birch triterpenesDrug

    Filsuvez topical gel: 10% birch triterpenes w/w in a colorless, slightly yellow gel supplied in 25 mL sterile tubes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the safety and tolerability of FilsuvezTime frame: 450 days-including follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.